It looks like nothing is going to get in the way of AGN tumbling to sub $100, even upbeat earnings and boosting yearly guidance only provided short term relief. This has been a nightmare for investors holding on hoping for a reversal, it teaches us all a lesson that no matter what the stock, once it goes out of favour it is very hard to reverse the negative sentiment and trend. The stock still remains a short unless some very positive news comes to the rescue, mergers or acquisitions are always a possibility.
AVERAGE ANALYSTS PRICE TARGET $177
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
COMPANY PROFILE
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.
AVERAGE ANALYSTS PRICE TARGET $177
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
COMPANY PROFILE
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.